It plays a key role in glucose and appetite regulation by: Stimulating insulin release (glucose-dependent) Suppressing glucagon secretion Slowing gastric emptying Increasing satiety and reducing appetite In people with type 2 diabetes, this GLP-1 response is impaired leading to poor glycemic control
In both Europe and the United States, the peptide has been approved as afamelanotide to prevent skin damage from sun exposure in patients with erythropoietic protoporphyria, a rare skin condition characterized by acute non-blistering photosensitivity, sunlight intolerance, and a significant reduction in quality of life [6]
Ideal for energy production, skin health, cognitive clarity and physical recovery
Patients who are starting GLP-1 treatment for the first time and prefer a needle-free option should note that Direct Meds' sublingual format is currently available for semaglutide only
use of drugs used to treat diabetes and cardiovascular disease, for example, insulin and renin-angiotensin system inhibitors
External Authority Organizations like the American Academy of Orthopaedic Surgeons (AAOS) stress caution with unapproved treatments, urging patients to seek guidance from board-certified specialists